



## RESS RELEASE

innate pharma

---

### IPH4102 PRECLINICAL DATA PUBLISHED IN "CANCER RESEARCH"

- *IPH4102 is a first-in-class anti-KIR3DL2 monoclonal antibody in development for the treatment of cutaneous T-cell lymphoma (CTCL). Phase I trial is expected to start in 2015*
- *IPH4102 shows potent efficacy in preclinical studies of advanced CTCL, published online in Cancer Research*
- *IPH4102 was recently granted orphan drug designation in the European Union for the treatment of CTCL*

Marseille, France, November 3, 2014

---

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announced that a peer-reviewed scientific article describing IPH4102 and results of preclinical efficacy studies was published online in Cancer Research, a journal of the American Association for Cancer Research.

The article published is entitled "*IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma*".

Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris, France, and co-author of the study, said: "*This study offers a preclinical proof of concept for clinical development of IPH4102, a novel monoclonal antibody therapy that targets KIR3DL2, one of the most relevant tumor antigens of cutaneous T-cell lymphoma, where there remains a high unmet medical need*".

Potent antitumor properties of IPH4102 were shown against human cutaneous T-cell lymphoma (CTCL) cells *in vitro* and *in vivo* in a mouse model of KIR3DL2+ tumors, in which IPH4102 reduced tumor growth and improved survival. The efficacy of IPH4102 was further evaluated in laboratory assays using the patients' own natural killer (NK) cells against their primary tumor samples in presence of IPH4102. These latter studies were performed in patients with Sézary Syndrome, the leukemic form of CTCL with the worst prognosis. In these experiments, IPH4102 selectively and efficiently induced killing of the patients' CTCL cells. Together, these results provide preclinical proof of concept supporting the clinical development of IPH4102 to treat advanced CTCL patients.

#### **About IPH4102:**

KIR3DL2 is an inhibitory receptor of the KIR family, normally expressed on a subset of normal NK cells and specifically expressed in most subtypes of the orphan indication of CTCL. CTCL is a group of rare cutaneous lymphomas of T lymphocytes with poor prognosis and few therapeutic options at advanced stages.

IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxic antibody, designed to selectively deplete CTCL cancer cells. IND-enabling studies with IPH4102 are currently ongoing and a Phase I trial is expected to start in 2015. IPH4102 was recently granted orphan drug status in



## RESS RELEASE

**innate** pharma

---

the European Union for the treatment of CTCL. Biomarker tools are being developed in parallel to monitor KIR3DL2 expression in patients.

### **About Innate Pharma:**

Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.

Its innovative approach has translated into major alliances with leaders in the biopharmaceutical industry such as Bristol-Myers Squibb and Novo Nordisk A/S.

The Company has two clinical-stage programs in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells. Innate Pharma science also has potential in chronic inflammatory diseases.

Listed on Euronext-Paris, Innate Pharma is based in Marseille, France, and had 90 employees as at June 30, 2014.

Learn more about Innate Pharma at [www.innate-pharma.com](http://www.innate-pharma.com).

### **Practical Information about Innate Pharma shares:**

**ISIN code** FR0010331421  
**Ticker code** IPH

### **Disclaimer:**

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (<http://www.amf-france.org>) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

### **For additional information, please contact:**

**Innate Pharma**  
Laure-Hélène Mercier  
Director, Investor Relations  
Tel.: +33 (0)4 30 30 30 87  
[investors@innate-pharma.com](mailto:investors@innate-pharma.com)

**ATCG Press**  
Judith Aziza, Mob.: +33 (0)6 70 07 77 51  
Marielle Bricman, Mob.: +33 (0)6 26 94 18 53  
[presse@atcg-partners.com](mailto:presse@atcg-partners.com)